- Plan to extend personal health budgets
- Ocrevus (ocrelizumab) a year on
- Differences in cognition for people with SPMS
Understanding MS is hard enough as an adult, but for the increasing numbers of young people affected by MS, it can be huge challenge. This MS Awareness Week (23-29th April), the MS Trust is highlighting the impact MS can have on young people.
- Lemtrada and possible new side effects
- Tysabri study in SPMS
- Fighting for housing rights
- Risk of infections when on DMDs
- NICE says no to ocrelizumab for RRMS
- Childbirth pain relief doesn't increase relapse risk
- Cognitive training helps memory
- Prescription charge increase
- Flying with a disability
A public consultation on guidance on the use of disease modifying drugs (DMDs) for people in England with relapsing MS is open until 5 May 2018
- Scottish MPs told of neurology recruitment crisis
- MS nurses criticise cumbersome disability benefits system
- Fears that funding for independent living may be under threat
Results from a large clinical trial of siponimod for secondary progressive MS (SPMS) have been published. Those taking siponimod had a 21% reduced risk of progression.
- Stem cell study for people with highly active relapsing MS shows promising results
- Caroline Wyatt talks about stem cell treatment
- Siponimod secondary progressive MS results published in Lancet
Sarah has signed up to take part in Miles for MS, our new distance challenge fundraising event. She tells us why she'll be walking 100 miles in May.